Semaglutide reduces risk for MACE in patients with obesity and heart failure
By
Haymarket Media
Aug 28, 2024
MACE, heart failure composite end point, cardiovascular death and all-cause death all improved with semaglutide for patients with versus without heart failure.
No spike in schizophrenia, other diagnoses among people with dementia after feds crack down on antipsychotic...
By
Kimberly Marselas
Aug 28, 2024
Federal policies designed to reduce use of antipsychotic medications in nursing homes did not lead to clinically significantly higher rates of schizophrenia diagnoses among people living with dementia,...
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.